"Eli Lilly's New Weight Loss Drug Strategy Shakes Up Market, Despite Pushback on Cosmetic Use"

Eli Lilly has launched a new direct-to-consumer service, LillyDirect, offering telehealth prescriptions and home delivery for certain drugs, including the weight loss treatment Zepbound. This move, a first for a major drugmaker, aims to bypass traditional drug distribution systems and provide more accessible and transparent pricing. While it may not immediately disrupt the industry, it could lead to more pharmaceutical companies adopting similar models, increasing pressure on the current complex drug supply chain. Analysts believe that while the traditional infrastructure involving PBMs will remain, Eli Lilly's approach could streamline access to medications and potentially influence drug pricing and distribution practices.